Proglumide Tablets

This product is a gastrin receptor antagonist, and its chemical structure is similar to the terminal chemical structure of two intestinal kinins, gastrin (G-17) and cholecystokinin (CCK). Its functional group amide group can specifically compete with gastrin for the gastrin receptor on the parietal cell, thus significantly inhibiting the secretion of gastric acid and pepsin caused by gastrin, but has no obvious effect on the gastric acid secretion caused by histamine and vagus nerve stimulation. It can increase the content of hexosamine in the gastric mucosa, promote glycoprotein synthesis, protect and promote the healing of the gastric mucosa, improve the symptoms of peptic ulcer and promote the healing of ulcer. The use of this product to treat peptic ulcer and gastritis does not cause the rebound phenomenon of gastric acid secretion, and the gastric acid secretion can still be kept at a normal level for up to half a year after the treatment is terminated. In addition, this product has a choleretic effect in three ways: ① by stimulating bile acid-independent bile secretion, it is beneficial to stone removal and flushing and dredging the bile duct; ② by changing the stone-forming factors in bile, the concentration and discharge of bicarbonate are significantly increased, while the concentration of free bilirubin, cholesterol and calcium ions are reduced; ③ by antagonizing CCK, inhibiting the gallbladder contraction-promoting effect of endogenous CCK, the gallbladder capacity is expanded, and the bile components in the gallbladder are diluted, thereby preventing stone formation. This product is safe, and the acute oral LD50 of mice is 17.8g/kg.

Proglumide. Its chemical name is (plusmn;)-5-dipropylamino-4-benzoylamino-5-oxo-pentanoic acid.

This product is white tablets.

Commonly used for gastric and duodenal ulcers, chronic superficial gastritis, and duodenal bulbitis.

Oral administration. Adults: 0.4g each time, 3-4 times a day, 15 minutes before meals, for 30-60 days. The medication time can also be determined according to the results of gastroscopy or X-ray examination. Children: 10-15mg/kg each time, 3 times a day, 15 minutes before meals. The course of treatment depends on the condition.

This product has no obvious side effects, but occasionally has adverse reactions such as dry mouth, constipation, itching, insomnia, abdominal distension, and lower limb soreness, which generally do not require special treatment; individual reports have reported temporary leukopenia and mild elevation of transaminase.

It is contraindicated in patients with complete obstruction of the cystic duct and bile duct.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

This product does not affect the metabolism of other drugs. If used simultaneously with other anti-ulcer drugs such as H2 receptor antagonists, it can enhance the inhibitory effect on gastric acid secretion and accelerate the healing of ulcers.

Keep away from light and store in sealed container.

0.2 g

24 months

Jilin Changbai Mountain Pharmaceutical Group Co., Ltd.

• Founded in:

  1996-10-18

• Address:

  No. 1, High-tech Industrial Park, Hunjiang District, Baishan City, Jilin Province (Economic Development Zone)

• Tax NO.:

  91220601717184476H

• Registered Funds:

  100 million yuan

• Email:

  Log in to view